Seizing the moment: The time for harnessing electronic patient-reported outcome measures for enhanced and sustainable metastatic breast cancer care is now
Breast. 2024 Feb 11;74:103676. doi: 10.1016/j.breast.2024.103676. Online ahead of print.ABSTRACTThe sustainability of healthcare systems is under pressure. Unlike care for many other chronic diseases, cancer care has yet to empower patients in effectively self-managing both the medical and emotional consequences of their condition, including adapting to changes in lifestyle and work, which is essential to achieve optimal health and recovery. Although proposed as a potential solution for sustainable healthcare and support for optimal health and recovery already decades ago, practical implementation of digital care lags behi...
Source: Breast - February 15, 2024 Category: Cancer & Oncology Authors: K M de Ligt L B Koppert B H de Rooij L V van de Poll-Franse G Velikova F Cardoso Source Type: research
Breast cancer highlights from 2023: Knowledge to guide practice and future research
Breast. 2024 Jan 27;74:103674. doi: 10.1016/j.breast.2024.103674. Online ahead of print.ABSTRACTThis narrative work highlights a selection of published work from 2023 with potential implications for breast cancer practice. We feature publications that have provided new knowledge immediately relevant to patient care or for future research. We also highlight guidelines that have reported evidence-based or consensus recommendations to support practice and evaluation in breast cancer diagnosis and treatment. The scope of selected highlights represents various domains and disciplines in cancer control, from prevention to treatm...
Source: Breast - February 10, 2024 Category: Cancer & Oncology Authors: Maria-Joao Cardoso Philip Poortmans El żbieta Senkus Oreste D Gentilini Nehmat Houssami Source Type: research
"The Uncertainty Principle"- studying immediate lymphatic reconstruction impacts the natural history of breast cancer related lymphedema
Breast. 2024 Feb 5;74:103678. doi: 10.1016/j.breast.2024.103678. Online ahead of print.ABSTRACTBreast cancer-related lymphedema (BCRL) following axillary lymph node dissection (ALND) is a life-altering sequela for patients and a challenging problem for their surgeons. In order to prevent BCRL, immediate lymphatic reconstruction (ILR) is a surgical technique that has been devised to restore lymphatic drainage to the operative limb. Although ILR is becoming popular in the literature, we have identified several challenges within our own ILR research, including a lack of a clear definition of lymphedema, a lack of common outco...
Source: Breast - February 10, 2024 Category: Cancer & Oncology Authors: Spencer Yakaback Claire Temple-Oberle Source Type: research
Local hero: A phase II study of local therapy only (stereotactic radiosurgery and / or surgery) for treatment of up to five brain metastases from HER2+ breast cancer. (TROG study 16.02)
Conclusion, At 12 months, SRS and/or neurosurgery provided good control with low toxicity. WBRT was not required in 95 % of cases. This small study supports the practice change from WBRT to local therapies for MHBC BrM.PMID:38340685 | DOI:10.1016/j.breast.2024.103675 (Source: Breast)
Source: Breast - February 10, 2024 Category: Cancer & Oncology Authors: Claire Phillips Mark B Pinkham Alisha Moore Joseph Sia Rosalind L Jeffree Mustafa Khasraw Anthony Kam Mathias Bressel Annette Haworth Source Type: research
De-escalation of loco-regional treatments: Time to find a balance
Breast. 2024 Jan 16;73:103673. doi: 10.1016/j.breast.2024.103673. Online ahead of print.NO ABSTRACTPMID:38295751 | PMC:PMC10844673 | DOI:10.1016/j.breast.2024.103673 (Source: Breast)
Source: Breast - January 31, 2024 Category: Cancer & Oncology Authors: Oreste D Gentilini Maria-Joao Cardoso El żbieta Senkus Philip Poortmans Source Type: research
Axillary lymph node dissection in triple-negative or HER2-positive breast cancer patients with clinical N2 achieving pathological complete response after neoadjuvant therapy: Is it necessary?
CONCLUSION: For cN2 TN or HER2+ breast cancer patients who achieve breast pCR following NAT, consideration could be given to downstaging and performing an axillary SLNB or TAD.PMID:38277714 | PMC:PMC10832498 | DOI:10.1016/j.breast.2024.103671 (Source: Breast)
Source: Breast - January 26, 2024 Category: Cancer & Oncology Authors: Xuhui Guo Jiao Zhang Xilong Gong Jia Wang Hao Dai Dechuang Jiao Rui Ling Yi Zhao Hongjian Yang Yunjiang Liu Ke Liu Jianguo Zhang Dahua Mao Jianjun He Zhigang Yu Yinhua Liu Peifen Fu Jiandong Wang Hongchuan Jiang Zuowei Zhao Xingsong Tian Zhongwei Cao Keji Source Type: research
"Heterogeneity of treatment effect on patients' long-term outcome according to pathological response type in neoadjuvant RCTs for breast cancer."
CONCLUSION: We reported new evidence that contributes to explaining the poor surrogacy value of pCR at trial-level in neoadjuvant RCTs for early-BC.PMID:38244459 | PMC:PMC10831306 | DOI:10.1016/j.breast.2024.103672 (Source: Breast)
Source: Breast - January 20, 2024 Category: Cancer & Oncology Authors: Laura Pala Isabella Sala Eleonora Pagan Tommaso De Pas Emma Zattarin Chiara Catania Emilia Cocorocchio Giovanna Rossi Daniele Laszlo Giovanni Ceresoli Jacopo Canzian Elena Valenzi Vincenzo Bagnardi Fabio Conforti Source Type: research
Diagnostic delays in breast cancer among young women: An emphasis on healthcare providers
Breast. 2023 Dec 13;73:103623. doi: 10.1016/j.breast.2023.103623. Online ahead of print.ABSTRACTDespite advances in breast cancer care, breast cancer in young women (BCYW) faces unique challenges, diagnostic delays, and limited awareness in many countries. Here, we discuss the challenges and consequences associated with the delayed diagnosis of BCYW. The consequences of delayed diagnosis in young women - which generally varies among developed, developing, or underdeveloped countries - are severe due to a faster breast tumor growth rate than tumors in older women, also contributing to advanced cancer stages and poorer outco...
Source: Breast - January 14, 2024 Category: Cancer & Oncology Authors: Luis Costa Rakesh Kumar Cynthia Villarreal-Garza Saket Sinha Sunil Saini Jayanti Semwal Vartika Saxsena Vaishali Zamre Chintamani Chintamani Mukurdipi Ray Chikako Shimizu Lejla Hadzikadic Gusic Masakazu Toi Allan Lipton Source Type: research
Omission of radiation therapy post breast conserving surgery
Breast. 2024 Jan 5;73:103670. doi: 10.1016/j.breast.2024.103670. Online ahead of print.ABSTRACTRadiation therapy (RT) after breast conserving surgery decreases the risks of local recurrence and breast cancer mortality in the multidisciplinary management of patients with breast cancer. However, breast cancer is a heterogeneous disease, and the absolute benefit of post-operative RT in individual patients varies substantially. Clinical trials aiming to identify patients with low-risk early breast cancer in whom post-operative RT may be safely omitted, based on conventional clinical-pathologic variables alone, have not provide...
Source: Breast - January 11, 2024 Category: Cancer & Oncology Authors: Boon H Chua Source Type: research
The oncological safety and long-term cosmetic effect of free dermal fat graft with epidermis removal for breast defect repair in breast conserving surgery
CONCLUSIONS: In this retrospective study, FDFG was significantly associated with an increased risk of local recurrence. Further prospective studies are required to confirm these results. No significant difference in long-term cosmetic effects were observed for FDFG than for BCS alone for immediate breast defect repair.PMID:38190791 | PMC:PMC10788852 | DOI:10.1016/j.breast.2023.103622 (Source: Breast)
Source: Breast - January 8, 2024 Category: Cancer & Oncology Authors: Zikui Xiong Jindi He Xin Zhao Xinqing Ye Manlu Cui Juan Fu Jianlun Liu Qiuyun Li Source Type: research
The oncological safety and long-term cosmetic effect of free dermal fat graft with epidermis removal for breast defect repair in breast conserving surgery
CONCLUSIONS: In this retrospective study, FDFG was significantly associated with an increased risk of local recurrence. Further prospective studies are required to confirm these results. No significant difference in long-term cosmetic effects were observed for FDFG than for BCS alone for immediate breast defect repair.PMID:38190791 | DOI:10.1016/j.breast.2023.103622 (Source: Breast)
Source: Breast - January 8, 2024 Category: Cancer & Oncology Authors: Zikui Xiong Jindi He Xin Zhao Xinqing Ye Manlu Cui Juan Fu Jianlun Liu Qiuyun Li Source Type: research
New insights into HER2-low breast cancer brain metastasis: A retrospective analysis
CONCLUSIONS: Patients diagnosed with HER2-low BCBM exhibited a more favorable prognosis than those with HER2-zero BCBM, particularly within the HR-negative subgroup. The low expression of HER2 is supposed to be linked to the prolonged survival of BCBM patients.PMID:38176304 | DOI:10.1016/j.breast.2023.103669 (Source: Breast)
Source: Breast - January 4, 2024 Category: Cancer & Oncology Authors: Hangcheng Xu Yan Wang Li Li Yiqun Han Yun Wu Qiang Sa Binghe Xu Jiayu Wang Source Type: research
Ten-year clinical outcome, toxicity and compliance of dose-dense sequential adjuvant administration of cyclophosphamide & amp; epirubicin followed by docetaxel in patients with early breast cancer: A hellenic cooperative oncology group observational study (HE 10/10) with concurrent investigation of significance of tumor infiltrating lymphocytes
CONCLUSIONS: In conclusion, this study confirms the significance of dds adjuvant chemotherapeutic regimen in terms of long-term survival outcome, safety and toxicity as well as the prognostic significance of TILs and infiltrating CD8+ lymphocytes in BC patients with early-stage disease.PMID:38176305 | DOI:10.1016/j.breast.2023.103668 (Source: Breast)
Source: Breast - January 4, 2024 Category: Cancer & Oncology Authors: Foteinos-Ioannis Dimitrakopoulos Anna Goussia Georgia-Angeliki Koliou Katerina Dadouli Anna Batistatou Helen P Kourea Mattheos Bobos Petroula Arapantoni-Dadioti Olympia Tzaida Triantafyllia Koletsa Sofia Chrisafi Maria Sotiropoulou Alexandra Papoudou-Bai Source Type: research
New insights into HER2-low breast cancer brain metastasis: A retrospective analysis
CONCLUSIONS: Patients diagnosed with HER2-low BCBM exhibited a more favorable prognosis than those with HER2-zero BCBM, particularly within the HR-negative subgroup. The low expression of HER2 is supposed to be linked to the prolonged survival of BCBM patients.PMID:38176304 | DOI:10.1016/j.breast.2023.103669 (Source: Breast)
Source: Breast - January 4, 2024 Category: Cancer & Oncology Authors: Hangcheng Xu Yan Wang Li Li Yiqun Han Yun Wu Qiang Sa Binghe Xu Jiayu Wang Source Type: research
Ten-year clinical outcome, toxicity and compliance of dose-dense sequential adjuvant administration of cyclophosphamide & amp; epirubicin followed by docetaxel in patients with early breast cancer: A hellenic cooperative oncology group observational study (HE 10/10) with concurrent investigation of significance of tumor infiltrating lymphocytes
CONCLUSIONS: In conclusion, this study confirms the significance of dds adjuvant chemotherapeutic regimen in terms of long-term survival outcome, safety and toxicity as well as the prognostic significance of TILs and infiltrating CD8+ lymphocytes in BC patients with early-stage disease.PMID:38176305 | DOI:10.1016/j.breast.2023.103668 (Source: Breast)
Source: Breast - January 4, 2024 Category: Cancer & Oncology Authors: Foteinos-Ioannis Dimitrakopoulos Anna Goussia Georgia-Angeliki Koliou Katerina Dadouli Anna Batistatou Helen P Kourea Mattheos Bobos Petroula Arapantoni-Dadioti Olympia Tzaida Triantafyllia Koletsa Sofia Chrisafi Maria Sotiropoulou Alexandra Papoudou-Bai Source Type: research
